Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 16h05 HE
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions -- Management to Host Webcast...
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
08 mai 2024 16h15 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12 mars 2024 16h05 HE
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector® - - Strengthened...
Global Macular Degeneration Treatment Market Forecast to 2031: Breakthrough in Durable Anti-VEGF Drugs Redefines Patient Care with Less Frequent Dosing
26 janv. 2024 06h27 HE
|
Research and Markets
Dublin, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The "Macular Degeneration Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
Retinal Biologics Global Market Report 2023: Innovations Key to Future Advances - Long-term Forecasts to 2028 and 2033
25 janv. 2024 09h33 HE
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Retinal Biologics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. Profound analytics indicate that the...
Retinopathy of Prematurity Research Reveals Market Insights, Epidemiology, and Forecast to 2032
24 janv. 2024 10h49 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Retinopathy of Prematurity - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. ...
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 nov. 2023 16h05 HE
|
Clearside Biomedical, Inc.
- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5...
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
08 nov. 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
01 nov. 2023 07h05 HE
|
Clearside Biomedical, Inc.
- Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Nov. 01, 2023 ...
Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023
31 oct. 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...